Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ORL015
MIFTS: 48

Oral Squamous Cell Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases, Rare diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Oral Squamous Cell Carcinoma

About this section

MalaCards integrated aliases for Oral Squamous Cell Carcinoma:

Name: Oral Squamous Cell Carcinoma 12 77 54 15 17
Squamous Cell Carcinoma of Mouth 74
Mouth Squamous Cell Carcinoma 12

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Oral diseases Skin diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0050866
UMLS 74 C0585362
Sources

Summaries for Oral Squamous Cell Carcinoma

About this section
Disease Ontology : 12 An oral cavity cancer that has material basis in squamous cells.

MalaCards based summary : Oral Squamous Cell Carcinoma, also known as squamous cell carcinoma of mouth, is related to squamous cell carcinoma and melanoma. An important gene associated with Oral Squamous Cell Carcinoma is MIR21 (MicroRNA 21), and among its related pathways/superpathways is LncRNA-mediated mechanisms of therapeutic resistance. The drugs Pentetic acid and Edetic Acid have been mentioned in the context of this disorder. Affiliated tissues include lymph node, endothelial and bone.

Wikipedia : 77 Squamous cell carcinomas (SCCs), also known as epidermoid carcinomas, comprise a number of different... more...

Sources

Related Diseases for Oral Squamous Cell Carcinoma

About this section

Diseases related to Oral Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 162)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 33.2 CCAT2 FOXCUT H19 HOTAIR MALAT1 NEAT1
2 melanoma 31.0 H19 HOTAIR MALAT1 MIR100 MIR137 MIR193A
3 esophageal cancer 30.7 CCAT1 H19 HOTAIR MALAT1 MIR21 UCA1
4 hepatocellular carcinoma 30.4 CCAT1 CCAT2 H19 HOTAIR MALAT1 MIR137
5 ovarian cancer 30.3 CCAT1 CCAT2 H19 HOTAIR MALAT1 MIR100
6 breast cancer 30.2 CCAT1 CCAT2 FOXCUT H19 HOTAIR MALAT1
7 leukoplakia 10.8
8 oral leukoplakia 10.7
9 lichen planus 10.6
10 oral lichen planus 10.6
11 oral submucous fibrosis 10.6
12 hypoxia 10.6
13 ovarian epithelial cancer 10.6 H19 HOTAIR MALAT1
14 triple-receptor negative breast cancer 10.6 HOTAIR MALAT1
15 pancreatic ductal adenocarcinoma 10.6 H19 HOTAIR MALAT1 MIR21 UCA1
16 pituitary adenoma 10.6 CCAT2 H19 HOTAIR MALAT1
17 small cell cancer of the lung 10.6 CCAT2 HOTAIR MALAT1 MIR21 TUG1
18 kidney cancer 10.5 H19 HOTAIR MALAT1 MIR21
19 thyroid cancer, nonmedullary, 1 10.5 H19 HOTAIR MALAT1 NEAT1
20 malignant glioma 10.5 CCAT1 HOTAIR NEAT1 TUG1
21 tongue squamous cell carcinoma 10.5 MALAT1 MIR21 UCA1
22 papilloma 10.5
23 glioblastoma 10.5 H19 HOTAIR MALAT1 MIR137 MIR21 TUG1
24 clear cell renal cell carcinoma 10.5 CCAT2 MALAT1 MIR21 TUG1
25 thyroid cancer 10.5 H19 HOTAIR MALAT1 NEAT1 UCA1
26 laryngeal squamous cell carcinoma 10.5 CCAT1 H19 HOTAIR MALAT1 MIR21 NEAT1
27 gallbladder cancer 10.5 CCAT1 H19 HOTAIR MALAT1 TUG1 UCA1
28 cholangiocarcinoma 10.5 CCAT2 H19 MALAT1 MIR21 NEAT1 TUG1
29 pre-eclampsia 10.5 H19 HOTAIR MALAT1 TUG1
30 myeloma, multiple 10.5 CCAT1 H19 HOTAIR MALAT1 TUG1 UCA1
31 gastrointestinal system cancer 10.5 H19 HOTAIR MALAT1
32 gastric cardia adenocarcinoma 10.5 H19 HOTAIR
33 leukemia, acute myeloid 10.5 CCAT1 HOTAIR MALAT1 MIR21 TUG1 UCA1
34 ovarian serous carcinoma 10.5 MIR100 MIR21
35 renal cell carcinoma, nonpapillary 10.5 CCAT1 H19 HOTAIR MALAT1 TUG1 UCA1
36 intrahepatic cholangiocarcinoma 10.5 CCAT1 CCAT2 TUG1
37 lung cancer susceptibility 3 10.5 CCAT1 H19 HOTAIR MALAT1 TUG1
38 bladder cancer 10.5 CCAT2 H19 HOTAIR MALAT1 MIR100 MIR21
39 osteogenic sarcoma 10.5 CCAT1 CCAT2 H19 HOTAIR MALAT1 NEAT1
40 adamantinoma of long bones 10.4 CCAT1 CCAT2 H19 HOTAIR MALAT1 NEAT1
41 glioma 10.4 CCAT1 CCAT2 H19 HOTAIR MALAT1 MIR21
42 astrocytoma 10.4 H19 HOTAIR MIR21
43 endometrial cancer 10.4 CCAT1 H19 HOTAIR NEAT1 TUG1 UCA1
44 cervical cancer 10.4 CCAT1 CCAT2 H19 HOTAIR MALAT1 MIR21
45 bladder urothelial carcinoma 10.4 HOTAIR MALAT1 TUG1
46 verrucous carcinoma 10.4
47 oral cancer 10.4
48 parkinson disease, late-onset 10.4 H19 HOTAIR MALAT1 NEAT1
49 nasopharyngeal carcinoma 10.4 CCAT1 FOXCUT H19 HOTAIR MALAT1 MIR100
50 pancreatic cancer 10.4 CCAT1 H19 HOTAIR MALAT1 MIR100 MIR21

Graphical network of the top 20 diseases related to Oral Squamous Cell Carcinoma:



Diseases related to Oral Squamous Cell Carcinoma
Sources

Symptoms & Phenotypes for Oral Squamous Cell Carcinoma

About this section
Sources

Drugs & Therapeutics for Oral Squamous Cell Carcinoma

About this section

Drugs for Oral Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 171)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pentetic acid Approved Phase 4 67-43-6
2
Edetic Acid Approved, Vet_approved Phase 4 62-33-9, 60-00-4 6049
3 arginine Phase 4,Phase 2
4 Omega 3 Fatty Acid Phase 4,Phase 2
5 Blood Substitutes Phase 4
6 Radiopharmaceuticals Phase 4,Not Applicable
7 Anticoagulants Phase 4
8 Dextrans Phase 4
9 Technetium Tc 99m Pentetate Phase 4
10 Chelating Agents Phase 4
11 Plasma Substitutes Phase 4
12 Technetium Tc 99m Sulfur Colloid Phase 4,Not Applicable
13
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
14
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
15
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 441203 84093 2767
16
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
17
Docetaxel Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 114977-28-5 148124
18
Metformin Approved Phase 3,Phase 2,Phase 1,Not Applicable 657-24-9 14219 4091
19
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
20
Zinc Approved, Investigational Phase 3,Phase 2 7440-66-6 32051
21
Indomethacin Approved, Investigational Phase 3,Phase 2 53-86-1 3715
22
Pilocarpine Approved, Investigational Phase 3 54-71-7, 92-13-7 5910
23
Bevacizumab Approved, Investigational Phase 3 216974-75-3
24
Carboplatin Approved Phase 3,Phase 2 41575-94-4 38904 10339178 498142
25
Cetuximab Approved Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
26
Durvalumab Approved, Investigational Phase 2, Phase 3,Phase 1 1428935-60-7
27 Kava Approved, Investigational, Nutraceutical Phase 3,Phase 2 9000-38-8
28 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
29 Antimetabolites Phase 3,Phase 2,Phase 1
30 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
31 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
32 Anti-Retroviral Agents Phase 3,Phase 2
33 Anti-HIV Agents Phase 3,Phase 2
34 Interleukin-2 Phase 3
35 Anti-Infective Agents Phase 3,Phase 2,Not Applicable
36 Antiviral Agents Phase 3,Phase 2,Early Phase 1
37 Antimitotic Agents Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1
38 Anti-Inflammatory Agents Phase 3,Phase 2
39 Peripheral Nervous System Agents Phase 3,Phase 2,Early Phase 1
40 Anti-Inflammatory Agents, Non-Steroidal Phase 3,Phase 2
41 Cyclooxygenase Inhibitors Phase 3,Phase 2
42 Analgesics Phase 3,Phase 2
43 Analgesics, Non-Narcotic Phase 3,Phase 2
44 Antirheumatic Agents Phase 3,Phase 2,Phase 1
45 Antibodies Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Mitogens Phase 3,Phase 2,Phase 1
47 Immunoglobulins Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
49 Hypoglycemic Agents Phase 3,Phase 2,Phase 1,Not Applicable
50 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 157)
# Name Status NCT ID Phase Drugs
1 Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Head & Neck Cancer Patients Completed NCT02622880 Phase 4
2 Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer Completed NCT02287675 Phase 4 Lymphoseek;Sulfur Colloid
3 Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL Unknown status NCT01039298 Phase 3
4 Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis. Unknown status NCT00964977 Phase 3
5 Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth Cancer Unknown status NCT00002747 Phase 3 cisplatin;fluorouracil
6 Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx Unknown status NCT00002702 Phase 3
7 TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma Completed NCT01542931 Phase 2, Phase 3 TPF induction chemotherapy
8 Cancer Chemoprevention by Metformin Hydrochloride in Oral Potentially Malignant Lesions Recruiting NCT03685409 Phase 3 Metformin Hydrochloride 500 MG;Placebo Oral Tablet
9 Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity Active, not recruiting NCT01265849 Phase 3 Cyclophosphamide;Indomethacin;Cisplatin
10 Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma Completed NCT00201279 Phase 3 13-cis Retino Acid
11 Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients Completed NCT00201383 Phase 3 cisplatin
12 Phase II Trial of Allovectin-7® for Head and Neck Cancer Completed NCT00050388 Phase 3
13 DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer Recruiting NCT03237325 Phase 3 SGX942;Placebo
14 Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00003139 Phase 3 pilocarpine hydrochloride
15 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
16 Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck Recruiting NCT02236936 Phase 3 Cisplatin
17 Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin Recruiting NCT03258554 Phase 2, Phase 3
18 Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma Unknown status NCT02739204 Phase 2 Celecoxib
19 Preoperative TPF Chemotherapy in a Population of Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer Unknown status NCT01914900 Phase 2 docetaxel, cisplatin, 5 fluorouracil
20 Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer Unknown status NCT00566540 Phase 2 Cisplatin;Paclitaxel
21 Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma Recruiting NCT03502148 Phase 1, Phase 2 PRV111 (Cisplatin Transmucosal System)
22 A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma Completed NCT00933387 Phase 2 Cetuximab,Paclitaxel,Cisplatin
23 A Dye for the Detection of Cancer of the Tongue and Mouth Recruiting NCT03085147 Phase 1, Phase 2 Olaparib
24 Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage Recruiting NCT02290145 Phase 2 TPF group
25 A Phase II Trial of TPF Induction Chemotherapy in cN2 OSCC Patients Active, not recruiting NCT02285543 Phase 2 TPF induction chemotherapy
26 GDF15 Based TPF Induction Chemotherapy for OSCC Patients Recruiting NCT02285530 Phase 2 TPF induction chemotherapy
27 Efficacy of Purslane in Treatment of Oral Lichen Planus Completed NCT00746772 Phase 2 Purslane 235mg/day in one dosage;Placebo : one dosage
28 Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study Recruiting NCT02748707 Phase 2 Arm1;Arm 2;Arm 3
29 Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention Completed NCT01192204 Phase 1, Phase 2 10% FBR containing bioadhesive gel;placebo gel
30 Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity Recruiting NCT03784066 Phase 1, Phase 2 Durvalumab
31 Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity Terminated NCT02331875 Phase 1, Phase 2 IPH2201
32 IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity Active, not recruiting NCT02609386 Phase 2 Cyclophosphamide;Indomethacin;Omeprazole
33 Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity Recruiting NCT02873819 Phase 2 GL-0817;Hiltonol;Sargramostim;cyclophosphamide;Placebo
34 Hypofractionated Radiation Therapy Followed by Surgery in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity Withdrawn NCT02295540 Phase 1, Phase 2
35 Photodynamic Therapy With HPPH in Treating Patients With Squamous Cell Carcinoma of the Oral Cavity Withdrawn NCT02119728 Phase 2 HPPH
36 Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity Recruiting NCT02919683 Phase 2 Nivolumab;Ipilimumab
37 GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer Completed NCT01553851 Phase 2 GSK1120212
38 Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil Terminated NCT00400205 Phase 2 Docetaxel;Cisplatin;5-fluorouracil
39 Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer Recruiting NCT03090412 Phase 2 HPPH;Photodynamic Therapy
40 CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer Not yet recruiting NCT03721757 Phase 2
41 ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment Recruiting NCT02917629 Phase 2 Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet
42 Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer Recruiting NCT03021993 Phase 2 Nivolumab
43 Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer Not yet recruiting NCT03575234 Phase 1, Phase 2 Cyclophosphamide
44 A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer Active, not recruiting NCT02508389 Phase 2 Low Dose GC4419: 30mg/day;High Dose GC4419: 90mg/day;Placebo
45 Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers Recruiting NCT03515538 Phase 2 RRx-001;Cisplatin for injection
46 Chemotherapy, Radiation Therapy, and Cetuximab in Treating Patients With the Head and Neck Cancer Completed NCT00875849 Phase 2 cisplatin
47 S0011, Gene Therapy & Surgery Followed by Chemo & RT in Newly Diagnosed Cancer of the Mouth or Throat Terminated NCT00017173 Phase 2 cisplatin
48 A Phase II Trial of a Protease Inhibitor, Nelfinavir (NFV), Given With Definitive, Concurrent Chemoradiotherapy (CTRT) in Patients With Locally-Advanced, Human Papilloma Virus (HPV) Negative, Squamous Cell Carcinoma of the Head and Neck Recruiting NCT02207439 Phase 2 Nelfinavir (Viracept®) 1250 mg;EF5
49 TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer Completed NCT01108042 Phase 1, Phase 2 Taxotere, Cisplatin, 5-Fluorouracil (5-FU)
50 A Trial of Perioperative Immune Enhancing Feed in Patients Undergoing Surgery for Head and Neck Cancer Completed NCT01314755 Phase 2

Search NIH Clinical Center for Oral Squamous Cell Carcinoma

Sources

Genetic Tests for Oral Squamous Cell Carcinoma

About this section
Sources

Anatomical Context for Oral Squamous Cell Carcinoma

About this section

MalaCards organs/tissues related to Oral Squamous Cell Carcinoma:

42
Lymph Node, Endothelial, Bone, Skin, T Cells, Neutrophil, Tongue
Sources

Publications for Oral Squamous Cell Carcinoma

About this section

Articles related to Oral Squamous Cell Carcinoma:

(show top 50) (show all 3851)
# Title Authors Year
1
Evaluation of salivary metabolomics in oral leukoplakia and oral squamous cell carcinoma. ( 30714209 )
2019
2
Combined Testing of p16 Tumour-suppressor Protein and Human Papillomavirus in Patients With Oral Leukoplakia and Oral Squamous Cell Carcinoma. ( 30842161 )
2019
3
Evaluation of enzymatic and non-enzymatic antioxidant status and biomarkers of oxidative stress in saliva of patients with oral squamous cell carcinoma and oral leukoplakia: a pilot study. ( 30857448 )
2019
4
The Elental® elemental diet for chemoradiotherapy-induced oral mucositis: A prospective study in patients with oral squamous cell carcinoma. ( 30655992 )
2019
5
Effect of Topical Application of Pure Honey in Chemo-radiation-Induced Mucositis and Its Clinical Benefits in Improving Quality of Life in Patients of Oral Squamous Cell Carcinoma. ( 30728696 )
2019
6
Tumoral microvesicle-activated glycometabolic reprogramming in fibroblasts promotes the progression of oral squamous cell carcinoma. ( 30698991 )
2019
7
Long non-coding RNA LINC00662 promotes proliferation and migration in oral squamous cell carcinoma. ( 30705593 )
2019
8
SPARC promotes the proliferation and metastasis of oral squamous cell carcinoma by PI3K/AKT/PDGFB/PDGFRβ axis. ( 30706473 )
2019
9
Risk factors for postoperative hemorrhage in patients with oral squamous cell carcinoma: A retrospective study. ( 30706556 )
2019
10
Multicenter retrospective study of the prognosis and treatment outcomes of Japanese oral squamous cell carcinoma patients with level IV/V metastasis. ( 30708395 )
2019
11
MicroRNA expression correlates with disease recurrence and overall survival in oral squamous cell carcinoma. ( 30709758 )
2019
12
Matrix Metalloproteinase 9 Inhibits the Motility of Highly Aggressive HSC-3 Oral Squamous Cell Carcinoma Cells. ( 30710501 )
2019
13
Saliva as a Diagnostic Tool in Oral Squamous Cell Carcinoma - a Systematic Review with Meta Analysis. ( 30712193 )
2019
14
The enigmatic role of matrix metalloproteinases in epithelial-to-mesenchymal transition of oral squamous cell carcinoma: Implications and nutraceutical aspects. ( 30714188 )
2019
15
MicroRNA‑199a‑5p functions as a tumor suppressor in oral squamous cell carcinoma via targeting the IKKβ/NF‑κB signaling pathway. ( 30720059 )
2019
16
lncRNA PLAC2 activated by H3K27 acetylation promotes cell proliferation and invasion via the activation of Wnt/β‑catenin pathway in oral squamous cell carcinoma. ( 30720068 )
2019
17
MiR-127-3p targets KIF3B to inhibit the development of oral squamous cell carcinoma. ( 30720171 )
2019
18
MicroRNA-625-3p promotes cell migration of oral squamous cell carcinoma by regulating SCAI expression. ( 30720172 )
2019
19
Long-term speech and swallowing function after primary resection and sentinel node biopsy for early oral squamous cell carcinoma. ( 30732950 )
2019
20
Obesity and genes related to lipid metabolism predict poor survival in oral squamous cell carcinoma. ( 30732952 )
2019
21
MicroRNA-1258, regulated by c-Myb, inhibits growth and epithelial-to-mesenchymal transition phenotype via targeting SP1 in oral squamous cell carcinoma. ( 30734471 )
2019
22
Touch Imprint Cytology: Can It Serve as an Alternative to Frozen Section in Intraoperative Assessment of Cervical Metastasis in Oral Squamous Cell Carcinoma? ( 30738065 )
2019
23
Cytoplasmic HMGB1 and HMGB1-Beclin1 complex are increased in radioresistant oral squamous cell carcinoma. ( 30738622 )
2019
24
Recurrent oral squamous cell carcinoma-incorporating advance care planning in education and practice. ( 30748030 )
2019
25
Correction to: Surface-enhanced Raman spectroscopy of blood serum based on gold nanoparticles for the diagnosis of the oral squamous cell carcinoma. ( 30760262 )
2019
26
Interferon-stimulated gene 15 modulates cell migration by interacting with Rac1 and contributes to lymph node metastasis of oral squamous cell carcinoma cells. ( 30765861 )
2019
27
LncRNA MINCR activates Wnt/β-catenin signals to promote cell proliferation and migration in oral squamous cell carcinoma. ( 30777615 )
2019
28
18F-FDG and 18F-FAMT PET-derived metabolic parameters predict outcome of oral squamous cell carcinoma. ( 30778900 )
2019
29
Prediction of lymph node metastasis in oral squamous cell carcinoma based on protein profile. ( 30779878 )
2019
30
A novel miR-365-3p/EHF/keratin 16 axis promotes oral squamous cell carcinoma metastasis, cancer stemness and drug resistance via enhancing β5-integrin/c-met signaling pathway. ( 30782177 )
2019
31
Exploration of pro-apoptotic effect of Thymoquinone on oral squamous cell carcinoma cells through PI3K/Akt signaling pathway. ( 30782296 )
2019
32
Identification of Portimine B, a New Cell Permeable Spiroimine That Induces Apoptosis in Oral Squamous Cell Carcinoma. ( 30783499 )
2019
33
Aberrant Collagen Cross-linking in Human Oral Squamous Cell Carcinoma. ( 30786814 )
2019
34
Dominant-negative p53 mutant R248Q increases the motile and invasive activities of oral squamous cell carcinoma cells. ( 30787262 )
2019
35
Divaricoside Exerts Antitumor Effects, in Part, by Modulating Mcl-1 in Human Oral Squamous Cell Carcinoma Cells. ( 30788081 )
2019
36
Extracellular vesicles derived from cancer-associated fibroblasts induce the migration and invasion of oral squamous cell carcinoma. ( 30788085 )
2019
37
Correlation analysis between the SUVmax of FDG-PET/CT and clinicopathological characteristics in oral squamous cell carcinoma. ( 30794427 )
2019
38
Downregulation of RGMA by HIF-1A/miR-210-3p axis promotes cell proliferation in oral squamous cell carcinoma. ( 30798120 )
2019
39
CDKL1 promotes the chemoresistance of human oral squamous cell carcinoma cells to hydroxycamptothecin. ( 30802495 )
2019
40
Study of Thymidylate Synthase (TS) and Dihydropyrimidine Dehydrogenase (DPD) Expressions on 5-Fluorouracil in Oral Squamous Cell Carcinoma ( 30803213 )
2019
41
The serum biomarker chemerin promotes tumorigenesis and metastasis in oral squamous cell carcinoma. ( 30804218 )
2019
42
Long noncoding RNA MORT overexpression inhibits cancer cell proliferation in oral squamous cell carcinoma by downregulating ROCK1. ( 30805944 )
2019
43
Progress in Drug and Formulation development for Chemoprevention of Oral Squamous Cell Carcinoma: A review. ( 30806332 )
2019
44
Synergistic Growth Inhibition by Afatinib and Trametinib in Preclinical Oral Squamous Cell Carcinoma Models. ( 30806895 )
2019
45
Tissue-infiltrating immune cells as prognostic markers in oral squamous cell carcinoma: a systematic review and meta-analysis. ( 30808992 )
2019
46
A Novel Multimodal NIR-II Nanoprobe for the Detection of Metastatic Lymph Nodes and Targeting Chemo-Photothermal Therapy in Oral Squamous Cell Carcinoma. ( 30809282 )
2019
47
LncRNA MEG3 suppresses migration and promotes apoptosis by sponging miR-548d-3p to modulate JAK-STAT pathway in oral squamous cell carcinoma. ( 30809930 )
2019
48
The Oncogenic Activity of miR-29b-1-5p Induces the Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma. ( 30813466 )
2019
49
Establishment and characterization of novel human oral squamous cell carcinoma cell lines from advanced‑stage tumors of buccal mucosa. ( 30816493 )
2019
50
Changes in the expression of the potassium channels TASK1, TASK3 and TRESK in a rat model of oral squamous cell carcinoma and their relation to malignancy. ( 30818127 )
2019
Sources

Variations for Oral Squamous Cell Carcinoma

About this section

Cosmic variations for Oral Squamous Cell Carcinoma:

9 (show top 50) (show all 1098)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM3724309 ZNF536 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1935G>C p.Q645H 19:30445497-30445497 0
2 COSM6976115 YES1 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1288C>T p.Q430* 18:736811-736811 0
3 COSM6914703 XPO1 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.619C>G p.Q207E 2:61498885-61498885 0
4 COSM6957917 TSC2 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1120A>T p.T374S 16:2061871-2061871 0
5 COSM121050 TP63 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.551C>T p.S184L 3:189808498-189808498 0
6 COSM10645 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.527G>T p.C176F 17:7675085-7675085 0
7 COSM69404 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.994-1G>A p.? 17:7670716-7670716 0
8 COSM11073 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1024C>T p.R342* 17:7670685-7670685 0
9 COSM43708 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.422G>A p.C141Y 17:7675190-7675190 0
10 COSM43947 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.614A>G p.Y205C 17:7674917-7674917 0
11 COSM44967 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.935C>G p.T312S 17:7673593-7673593 0
12 COSM44561 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.454C>A p.P152T 17:7675158-7675158 0
13 COSM10727 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.438G>A p.W146* 17:7675174-7675174 0
14 COSM11084 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.517G>A p.V173M 17:7675095-7675095 0
15 COSM10758 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.659A>G p.Y220C 17:7674872-7674872 0
16 COSM10958 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.797G>T p.G266V 17:7673823-7673823 0
17 COSM43850 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.659A>C p.Y220S 17:7674872-7674872 0
18 COSM43606 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.734G>A p.G245D 17:7674229-7674229 0
19 COSM10648 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.524G>A p.R175H 17:7675088-7675088 0
20 COSM43665 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.746G>C p.R249T 17:7674217-7674217 0
21 COSM44351 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.572C>T p.P191L 17:7674959-7674959 0
22 COSM10663 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.916C>T p.R306* 17:7673704-7673704 0
23 COSM10756 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.827C>T p.A276V 17:7673793-7673793 0
24 COSM10659 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.817C>T p.R273C 17:7673803-7673803 0
25 COSM43695 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.748C>T p.P250S 17:7674215-7674215 0
26 COSM44229 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.515T>A p.V172D 17:7675097-7675097 0
27 COSM44935 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.724T>A p.C242S 17:7674239-7674239 0
28 COSM10704 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.844C>T p.R282W 17:7673776-7673776 0
29 COSM10646 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.725G>A p.C242Y 17:7674238-7674238 0
30 COSM43714 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.836G>A p.G279E 17:7673784-7673784 0
31 COSM43743 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.914A>G p.K305R 17:7673706-7673706 0
32 COSM10905 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.451C>T p.P151S 17:7675161-7675161 0
33 COSM10656 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.742C>T p.R248W 17:7674221-7674221 0
34 COSM44823 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.981T>G p.Y327* 17:7673547-7673547 0
35 COSM10662 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 0
36 COSM10735 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.638G>A p.R213Q 17:7674893-7674893 0
37 COSM43559 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.517G>T p.V173L 17:7675095-7675095 0
38 COSM43906 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.843C>A p.D281E 17:7673777-7673777 0
39 COSM10724 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.839G>C p.R280T 17:7673781-7673781 0
40 COSM43680 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.523C>T p.R175C 17:7675089-7675089 0
41 COSM43772 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.538G>A p.E180K 17:7675074-7675074 0
42 COSM10863 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.833C>T p.P278L 17:7673787-7673787 0
43 COSM44393 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.821T>C p.V274A 17:7673799-7673799 0
44 COSM10728 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.839G>A p.R280K 17:7673781-7673781 0
45 COSM11286 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1015G>T p.E339* 17:7670694-7670694 0
46 COSM10660 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.818G>A p.R273H 17:7673802-7673802 0
47 COSM10808 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.488A>G p.Y163C 17:7675124-7675124 0
48 COSM10788 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.764T>G p.I255S 17:7674199-7674199 0
49 COSM44449 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.415A>G p.K139E 17:7675197-7675197 0
50 COSM10893 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.824G>A p.C275Y 17:7673796-7673796 0

Copy number variations for Oral Squamous Cell Carcinoma from CNVD:

7 (show top 50) (show all 164)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 41848 10 24600000 38000000 Deletion Oral squamous cell carcinoma
2 49706 11 110400000 121200000 Deletion Oral squamous cell carcinoma
3 50988 11 121200000 130800000 Deletion Oral squamous cell carcinoma
4 51497 11 12700000 16200000 Deletion Oral squamous cell carcinoma
5 57445 11 63400000 77100000 Amplification CCND1 Oral squamous cell carcinoma
6 57446 11 63400000 77100000 Amplification EMS1 Oral squamous cell carcinoma
7 57448 11 63400000 77100000 Amplification FGF3 Oral squamous cell carcinoma
8 57449 11 63400000 77100000 Amplification FGF4 Oral squamous cell carcinoma
9 57450 11 63400000 77100000 Amplification PPP1CA Oral squamous cell carcinoma
10 57451 11 63400000 77100000 Amplification TAOS1 Oral squamous cell carcinoma
11 58782 11 69471367 69490165 Amplification ORAOV1 Oral squamous cell carcinoma
12 74065 13 1 4500000 Deletion Oral squamous cell carcinoma
13 74179 13 101700000 110300000 Deletion Oral squamous cell carcinoma
14 75170 13 17900000 115169878 Noncopy numberrandom LOH Oral squamous cell carcinoma
15 76133 13 27800000 55300000 Deletion Oral squamous cell carcinoma
16 76134 13 27800000 87700000 Deletion Oral squamous cell carcinoma
17 76220 13 28900000 40100000 Deletion Oral squamous cell carcinoma
18 76534 13 32200000 40100000 Deletion Oral squamous cell carcinoma
19 76709 13 35500000 40100000 Deletion Oral squamous cell carcinoma
20 77109 13 40100000 59600000 Deletion Oral squamous cell carcinoma
21 78640 13 55300000 73300000 Deletion Oral squamous cell carcinoma
22 79281 13 68600000 87700000 Deletion Oral squamous cell carcinoma
23 79539 13 73300000 79000000 Deletion Oral squamous cell carcinoma
24 79879 13 79000000 87700000 Deletion Oral squamous cell carcinoma
25 80342 13 90000000 98200000 Deletion Oral squamous cell carcinoma
26 80629 13 95000000 110300000 Deletion Oral squamous cell carcinoma
27 80632 13 95000000 115169878 Deletion Oral squamous cell carcinoma
28 80634 13 95000000 98200000 Deletion Oral squamous cell carcinoma
29 83034 14 19100000 33300000 Deletion Oral squamous cell carcinoma
30 84231 14 24600000 33300000 Deletion Oral squamous cell carcinoma
31 85052 14 37800000 50900000 Deletion Oral squamous cell carcinoma
32 86340 14 58100000 67900000 Deletion Oral squamous cell carcinoma
33 86341 14 58100000 73800000 Deletion Oral squamous cell carcinoma
34 87452 14 73800000 79300000 Deletion Oral squamous cell carcinoma
35 89133 15 1 19000000 Noncopy numberrandom LOH Oral squamous cell carcinoma
36 90246 15 20700000 40100000 Deletion Oral squamous cell carcinoma
37 91779 15 33600000 40100000 Deletion Oral squamous cell carcinoma
38 91783 15 33600000 44800000 Deletion Oral squamous cell carcinoma
39 92363 15 40100000 49500000 Deletion Oral squamous cell carcinoma
40 92861 15 44800000 49500000 Deletion Oral squamous cell carcinoma
41 93371 15 52900000 72700000 Deletion Oral squamous cell carcinoma
42 95627 15 78300000 89100000 Deletion Oral squamous cell carcinoma
43 95629 15 78300000 98500000 Deletion Oral squamous cell carcinoma
44 106754 17 1 16000000 Deletion Oral squamous cell carcinoma
45 106831 17 1 24000000 Noncopy numberrandom LOH Oral squamous cell carcinoma
46 106907 17 1 81195210 Deletion Oral squamous cell carcinoma
47 106970 17 10700000 50200000 Deletion Oral squamous cell carcinoma
48 109058 17 24000000 81195210 Noncopy numberrandom LOH Oral squamous cell carcinoma
49 112186 17 38100000 57600000 Deletion Oral squamous cell carcinoma
50 114590 17 50200000 70900000 Deletion Oral squamous cell carcinoma
Sources

Expression for Oral Squamous Cell Carcinoma

About this section
Search GEO for disease gene expression data for Oral Squamous Cell Carcinoma.
Sources

Pathways for Oral Squamous Cell Carcinoma

About this section

Pathways related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
LncRNA-mediated mechanisms of therapeutic resistance 1
9.7 HOTAIR UCA1
Sources

GO Terms for Oral Squamous Cell Carcinoma

About this section

Cellular components related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 micro-ribonucleoprotein complex GO:0035068 9.1 H19 MIR100 MIR137 MIR193A MIR21 NEAT1

Biological processes related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of angiogenesis GO:0016525 9.33 MIR137 MIR193A MIR21
2 negative regulation of blood vessel endothelial cell migration GO:0043537 9.32 MIR137 MIR193A
3 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.26 MIR137 MIR21
4 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.13 MIR137 MIR193A MIR21
5 gene silencing by miRNA GO:0035195 9.1 H19 MIR100 MIR137 MIR193A MIR21 NEAT1
Sources

Sources for Oral Squamous Cell Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....